Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II, Randomized, Double Blind, Parallel Group,46 Weeks Dose-finding Study of BI 456906 Administered Once Weekly Subcutaneously Compared With Placebo in Patients With Obesity or Overweight

Trial Profile

A Phase II, Randomized, Double Blind, Parallel Group,46 Weeks Dose-finding Study of BI 456906 Administered Once Weekly Subcutaneously Compared With Placebo in Patients With Obesity or Overweight

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 24 Mar 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Survodutide (Primary)
  • Indications Obesity
  • Focus Proof of concept; Therapeutic Use
  • Sponsors Boehringer Ingelheim

Most Recent Events

  • 19 Mar 2025 Results of subgroup analysis by age assessing baseline BMI in people with a BMI ≥27 kg/m2 published in the Diabetes, Obesity and Metabolism
  • 16 May 2024 According to a Zealand Pharma media release, the topline results will be presented at the European Association for the Study of the Liver (EASL) congress in Milan, Italy on June 7, 2024.
  • 16 May 2024 Results presented in the Zealand Pharma media release.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top